Search results
Results from the WOW.Com Content Network
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment ... market will grow at 11% a year through 2033 to $5.7 billion. ... market to grow by 13% a year to ...
The IPO market, particularly technology and fintech, has been rebuilding for a number of quarters, and we expect the market to open up more broadly next year across many core sectors, including ...
For premium support please call: 800-290-4726 more ways to reach us
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
This page was last edited on 3 February 2024, at 22:53 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
Need help? Call us! 800-290-4726 Login / Join. Mail
The two companies had agreed to a $54 billion deal that would allow AbbVie to move its headquarters overseas to Europe, reducing their corporate tax rate. However, the U.S. Treasury passed laws, tightening down on tax inversion deals just before the merger was completed, making the agreement much less profitable for AbbVie. [citation needed] 15 ...